MovDisordV3, PascalFrancis, Corpus, bibRecord, 003549

Peripheral and central pharmacokinetics of apomorphine and its effect on dopamine metabolism in humans

Identifieur interne : 003549 ( PascalFrancis/Corpus ); précédent : 003548; suivant : 003550

Peripheral and central pharmacokinetics of apomorphine and its effect on dopamine metabolism in humans

Auteurs : S. Przedborski ; M. Levivier ; C. Raftopoulos ; A. B. Naini ; J. Hildebrand

Source :

Movement disorders [ 0885-3185 ] ; 1995.

RBID : Pascal:95-0167516

Descripteurs français

Pascal (Inist)
- Apomorphine, Agoniste, Récepteur dopaminergique, Antiparkinsonien, Pharmacocinétique, Homme, Voie souscutanée, Plasma sanguin, Liquide céphalorachidien.

English descriptors

KwdEn :
- Agonist, Antiparkinson agent, Blood plasma, Cerebrospinal fluid, Dopamine receptor, Human, Pharmacokinetics, Subcutaneous administration.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0885-3185`
A03		`1`		`@0 Mov. disord.`
A05				`@2 10`
A06				`@2 1`
A08	`01`	`1`	`ENG`	`@1 Peripheral and central pharmacokinetics of apomorphine and its effect on dopamine metabolism in humans`
A11	`01`	`1`		`@1 PRZEDBORSKI (S.)`
A11	`02`	`1`		`@1 LEVIVIER (M.)`
A11	`03`	`1`		`@1 RAFTOPOULOS (C.)`
A11	`04`	`1`		`@1 NAINI (A. B.)`
A11	`05`	`1`		`@1 HILDEBRAND (J.)`
A14	`01`			`@1 Univ. libre Bruxelles, hôp. Erasme, dep. neurology @2 Brussels @3 BEL @Z 1 aut. @Z 5 aut.`
A20				`@1 28-36`
A21				`@1 1995`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20953 @5 354000058100400050`
A44				`@0 0000`
A45				`@0 38 ref.`
A47	`01`	`1`		`@0 95-0167516`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Movement disorders`
A66	`01`			`@0 USA`
C02	`01`	`X`		`@0 002B02B06`
C03	`01`	`X`	`FRE`	`@0 Apomorphine @2 NK @2 FR @5 01`
C03	`02`	`X`	`FRE`	`@0 Agoniste @5 02`
C03	`02`	`X`	`ENG`	`@0 Agonist @5 02`
C03	`02`	`X`	`SPA`	`@0 Agonista @5 02`
C03	`03`	`X`	`FRE`	`@0 Récepteur dopaminergique @5 03`
C03	`03`	`X`	`ENG`	`@0 Dopamine receptor @5 03`
C03	`03`	`X`	`SPA`	`@0 Receptor dopaminérgico @5 03`
C03	`04`	`X`	`FRE`	`@0 Antiparkinsonien @5 16`
C03	`04`	`X`	`ENG`	`@0 Antiparkinson agent @5 16`
C03	`04`	`X`	`SPA`	`@0 Antiparkinsoniano @5 16`
C03	`05`	`X`	`FRE`	`@0 Pharmacocinétique @5 17`
C03	`05`	`X`	`ENG`	`@0 Pharmacokinetics @5 17`
C03	`05`	`X`	`SPA`	`@0 Farmacocinética @5 17`
C03	`06`	`X`	`FRE`	`@0 Homme @5 20`
C03	`06`	`X`	`ENG`	`@0 Human @5 20`
C03	`06`	`X`	`SPA`	`@0 Hombre @5 20`
C03	`07`	`X`	`FRE`	`@0 Voie souscutanée @5 23`
C03	`07`	`X`	`ENG`	`@0 Subcutaneous administration @5 23`
C03	`07`	`X`	`SPA`	`@0 Vía subcutánea @5 23`
C03	`08`	`X`	`FRE`	`@0 Plasma sanguin @5 35`
C03	`08`	`X`	`ENG`	`@0 Blood plasma @5 35`
C03	`08`	`X`	`SPA`	`@0 Plasma sanguíneo @5 35`
C03	`09`	`X`	`FRE`	`@0 Liquide céphalorachidien @5 36`
C03	`09`	`X`	`ENG`	`@0 Cerebrospinal fluid @5 36`
C03	`09`	`X`	`SPA`	`@0 Líquido cefalorraquídeo @5 36`
C07	`01`	`X`	`FRE`	`@0 Chimiothérapie @5 37`
C07	`01`	`X`	`ENG`	`@0 Chemotherapy @5 37`
C07	`01`	`X`	`SPA`	`@0 Quimioterapia @5 37`
N21				`@1 095`

Format Inist (serveur)

NO :	PASCAL 95-0167516 INIST
ET :	Peripheral and central pharmacokinetics of apomorphine and its effect on dopamine metabolism in humans
AU :	PRZEDBORSKI (S.); LEVIVIER (M.); RAFTOPOULOS (C.); NAINI (A. B.); HILDEBRAND (J.)
AF :	Univ. libre Bruxelles, hôp. Erasme, dep. neurology/Brussels/Belgique (1 aut., 5 aut.)
DT :	Publication en série; Niveau analytique
SO :	Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 1995; Vol. 10; No. 1; Pp. 28-36; Bibl. 38 ref.
LA :	Anglais
CC :	002B02B06
FD :	Apomorphine; Agoniste; Récepteur dopaminergique; Antiparkinsonien; Pharmacocinétique; Homme; Voie souscutanée; Plasma sanguin; Liquide céphalorachidien
FG :	Chimiothérapie
ED :	Agonist; Dopamine receptor; Antiparkinson agent; Pharmacokinetics; Human; Subcutaneous administration; Blood plasma; Cerebrospinal fluid
EG :	Chemotherapy
SD :	Agonista; Receptor dopaminérgico; Antiparkinsoniano; Farmacocinética; Hombre; Vía subcutánea; Plasma sanguíneo; Líquido cefalorraquídeo
LO :	INIST-20953.354000058100400050
ID :	95-0167516

Links to Exploration step

Pascal:95-0167516

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Peripheral and central pharmacokinetics of apomorphine and its effect on dopamine metabolism in humans</title>
<author><name sortKey="Przedborski, S" sort="Przedborski, S" uniqKey="Przedborski S" first="S." last="Przedborski">S. Przedborski</name>
<affiliation><inist:fA14 i1="01"><s1>Univ. libre Bruxelles, hôp. Erasme, dep. neurology</s1>
<s2>Brussels</s2>
<s3>BEL</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Levivier, M" sort="Levivier, M" uniqKey="Levivier M" first="M." last="Levivier">M. Levivier</name>
</author>
<author><name sortKey="Raftopoulos, C" sort="Raftopoulos, C" uniqKey="Raftopoulos C" first="C." last="Raftopoulos">C. Raftopoulos</name>
</author>
<author><name sortKey="Naini, A B" sort="Naini, A B" uniqKey="Naini A" first="A. B." last="Naini">A. B. Naini</name>
</author>
<author><name sortKey="Hildebrand, J" sort="Hildebrand, J" uniqKey="Hildebrand J" first="J." last="Hildebrand">J. Hildebrand</name>
<affiliation><inist:fA14 i1="01"><s1>Univ. libre Bruxelles, hôp. Erasme, dep. neurology</s1>
<s2>Brussels</s2>
<s3>BEL</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">95-0167516</idno>
<date when="1995">1995</date>
<idno type="stanalyst">PASCAL 95-0167516 INIST</idno>
<idno type="RBID">Pascal:95-0167516</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">003549</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Peripheral and central pharmacokinetics of apomorphine and its effect on dopamine metabolism in humans</title>
<author><name sortKey="Przedborski, S" sort="Przedborski, S" uniqKey="Przedborski S" first="S." last="Przedborski">S. Przedborski</name>
<affiliation><inist:fA14 i1="01"><s1>Univ. libre Bruxelles, hôp. Erasme, dep. neurology</s1>
<s2>Brussels</s2>
<s3>BEL</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Levivier, M" sort="Levivier, M" uniqKey="Levivier M" first="M." last="Levivier">M. Levivier</name>
</author>
<author><name sortKey="Raftopoulos, C" sort="Raftopoulos, C" uniqKey="Raftopoulos C" first="C." last="Raftopoulos">C. Raftopoulos</name>
</author>
<author><name sortKey="Naini, A B" sort="Naini, A B" uniqKey="Naini A" first="A. B." last="Naini">A. B. Naini</name>
</author>
<author><name sortKey="Hildebrand, J" sort="Hildebrand, J" uniqKey="Hildebrand J" first="J." last="Hildebrand">J. Hildebrand</name>
<affiliation><inist:fA14 i1="01"><s1>Univ. libre Bruxelles, hôp. Erasme, dep. neurology</s1>
<s2>Brussels</s2>
<s3>BEL</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="1995">1995</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Agonist</term>
<term>Antiparkinson agent</term>
<term>Blood plasma</term>
<term>Cerebrospinal fluid</term>
<term>Dopamine receptor</term>
<term>Human</term>
<term>Pharmacokinetics</term>
<term>Subcutaneous administration</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Apomorphine</term>
<term>Agoniste</term>
<term>Récepteur dopaminergique</term>
<term>Antiparkinsonien</term>
<term>Pharmacocinétique</term>
<term>Homme</term>
<term>Voie souscutanée</term>
<term>Plasma sanguin</term>
<term>Liquide céphalorachidien</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>10</s2>
</fA05>
<fA06><s2>1</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Peripheral and central pharmacokinetics of apomorphine and its effect on dopamine metabolism in humans</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>PRZEDBORSKI (S.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>LEVIVIER (M.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>RAFTOPOULOS (C.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>NAINI (A. B.)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>HILDEBRAND (J.)</s1>
</fA11>
<fA14 i1="01"><s1>Univ. libre Bruxelles, hôp. Erasme, dep. neurology</s1>
<s2>Brussels</s2>
<s3>BEL</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
</fA14>
<fA20><s1>28-36</s1>
</fA20>
<fA21><s1>1995</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000058100400050</s5>
</fA43>
<fA44><s0>0000</s0>
</fA44>
<fA45><s0>38 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>95-0167516</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC02 i1="01" i2="X"><s0>002B02B06</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Apomorphine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Agoniste</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Agonist</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Agonista</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Récepteur dopaminergique</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Dopamine receptor</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Receptor dopaminérgico</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Antiparkinsonien</s0>
<s5>16</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Antiparkinson agent</s0>
<s5>16</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Antiparkinsoniano</s0>
<s5>16</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Pharmacocinétique</s0>
<s5>17</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Pharmacokinetics</s0>
<s5>17</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Farmacocinética</s0>
<s5>17</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Homme</s0>
<s5>20</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Human</s0>
<s5>20</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Hombre</s0>
<s5>20</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Voie souscutanée</s0>
<s5>23</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Subcutaneous administration</s0>
<s5>23</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Vía subcutánea</s0>
<s5>23</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Plasma sanguin</s0>
<s5>35</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Blood plasma</s0>
<s5>35</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Plasma sanguíneo</s0>
<s5>35</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Liquide céphalorachidien</s0>
<s5>36</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Cerebrospinal fluid</s0>
<s5>36</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Líquido cefalorraquídeo</s0>
<s5>36</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Chimiothérapie</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Chemotherapy</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Quimioterapia</s0>
<s5>37</s5>
</fC07>
<fN21><s1>095</s1>
</fN21>
</pA>
</standard>
<server><NO>PASCAL 95-0167516 INIST</NO>
<ET>Peripheral and central pharmacokinetics of apomorphine and its effect on dopamine metabolism in humans</ET>
<AU>PRZEDBORSKI (S.); LEVIVIER (M.); RAFTOPOULOS (C.); NAINI (A. B.); HILDEBRAND (J.)</AU>
<AF>Univ. libre Bruxelles, hôp. Erasme, dep. neurology/Brussels/Belgique (1 aut., 5 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 1995; Vol. 10; No. 1; Pp. 28-36; Bibl. 38 ref.</SO>
<LA>Anglais</LA>
<CC>002B02B06</CC>
<FD>Apomorphine; Agoniste; Récepteur dopaminergique; Antiparkinsonien; Pharmacocinétique; Homme; Voie souscutanée; Plasma sanguin; Liquide céphalorachidien</FD>
<FG>Chimiothérapie</FG>
<ED>Agonist; Dopamine receptor; Antiparkinson agent; Pharmacokinetics; Human; Subcutaneous administration; Blood plasma; Cerebrospinal fluid</ED>
<EG>Chemotherapy</EG>
<SD>Agonista; Receptor dopaminérgico; Antiparkinsoniano; Farmacocinética; Hombre; Vía subcutánea; Plasma sanguíneo; Líquido cefalorraquídeo</SD>
<LO>INIST-20953.354000058100400050</LO>
<ID>95-0167516</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003549 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 003549 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:95-0167516
   |texte=   Peripheral and central pharmacokinetics of apomorphine and its effect on dopamine metabolism in humans
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Peripheral and central pharmacokinetics of apomorphine and its effect on dopamine metabolism in humans

Peripheral and central pharmacokinetics of apomorphine and its effect on dopamine metabolism in humans

Source :

Descripteurs français

English descriptors

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri